ProCE Banner Activity

KEYNOTE-564: Adjuvant Pembrolizumab vs Placebo After Nephrectomy for Renal Cell Carcinoma

Slideset Download
Conference Coverage
Results of the first interim analysis for this randomized, double-blind phase III trial demonstrated significantly improved DFS with adjuvant pembrolizumab in patients with clear-cell RCC following nephrectomy.

Released: June 11, 2021

Expiration: June 10, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme